TOP STORIES
Johnson & Johnson (NYSE: JNJ) has accepted Cardinal Health‘s $2 billion offer to acquire vascular medical device producer, Cordis.
Teva reached a $1.2 billion settlement with the Federal Trade Commission over
claims that Cephalon illegally blocked generics that competed with its sleep-disorder drug Provigil. It marked the first time the FTC had received a financial settlement for drug purchasers in a “pay for delay” case, according to The Wall Street Journal.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Otsuka Pharmaceutical Co Ltd lost a lawsuit challenging the U.S. Food and Drug Administration’s decision allowing other companies to make generic versions of the it’s antipsychotic drug, Abilify. Because the FDA typically grants years of exclusivity for “orphan drugs,” Otsuka believed it had the right to produce the drug exclusively until 2021 because of it’s designation as an orphan drug.
LIFE SCIENCES
In a curtain raiser on the American Society of Clinical Oncology annual meeting, life science investor Bruce Booth offers a data analysis of the nearly 5,000 papers being presented at the conference.
Following in the footsteps of Par Pharmaceuticals and Allergan, Amarin views sales and marketing language as a free speech issue in a lawsuit against the FDA.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Cancer diagnostic startup Armune Bioscience developed the first cancer-specific prostate test called Apifiny.
AstraZeneca and Lilly are combining their cancer drugs to combat solid tumors including AstraZeneca’s anti-PD-L1 immunotherapy drug MEDI4736 and Lilly’s approved drug Cyramza, or ramucirumab in a Phase 1 clinical trial by Lilly.
Contract research organization Quintiles has officially opened officed in Shanghai.
PAYERS-PROVIDERS
Two antitrust suits are making their way through an Alabama federal court claim Blue Cross Blue Shield companies are acting like a cartel by dividing up markets in order to avoid competition. The Blue Cross Blue Shield Association is also named in the suits.
According to a new study published by JAMA Internal Medicine, telehealth providers were more likely to prescribe costly medication than traditional health providers. Doctors who operate via telehealth are just as likely to prescribe antibiotics as doctors who see patients in person.
Why are doctors quitting? Charles Krauthammer seems to think overburdensome regulations in Obamacare are driving doctors from the profession, but the lively debate in the comments section suggests everything from the computerization of healthcare to reimbursements and the high cost of converting to electronic health records for smaller practices.
TECH
Chicago Cardiology Institute has deployed TigerText to accelerate clinician response times.
Sydney-based Genea developed a smartphone app to track in vitro fertilization and help doctors and parents monitor a growing embryo thousands of miles away.
POLITICS
A new rule under the Obama administration states that insurance companies managing Medicaid plans must spend at least 85 percent of their revenues on medical care.
Republicans have challenged the Obama administration by claiming that President Obama is unconstitutionally spending funds under Obamacare that Congress has not yet appropriated.
A LITTLE EXTRA
Designing robots that are able to adapt to certain circumstances, similar to a biological animal, such as being injured, is an emerging trend. A study of robot adaptation was published in Nature this week.
The Morning Read provides a 24-hour wrap up of everything else healthcare’s innovators need to know about the business of medicine (and beyond). The author of The Read published it but all full-time MedCity News journalists contribute to its content.
Photo: Getty
